We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current NBRV market cap is 0. The company's latest EPS is USD and P/E is N/A.
| Quarter End | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 9.25M | 8.02M | 9.41M | 9.51M | 10.57M |
| Operating Income | -12.89M | -11.56M | -10.18M | -10.85M | -22.33M |
| Net Income | -13.06M | -11.82M | -11.07M | -11.51M | -22.78M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 9.66M | 9.7M | 6.21M | 29.36M | 37.51M |
| Operating Income | -114.65M | -79.27M | -64.94M | -48.06M | -54.92M |
| Net Income | -114.78M | -82.76M | -69.48M | -49.45M | -57.19M |
| Quarter End | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 80.91M | 65.78M | 54.89M | 48.24M | 31.77M |
| Total Liabilities | 27.56M | 21.16M | 20.29M | 22.62M | 28.47M |
| Total Equity | 53.35M | 44.63M | 34.61M | 25.62M | 3.29M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 110.42M | 94.11M | 58.44M | 80.91M | 31.77M |
| Total Liabilities | 41.79M | 52.84M | 25.3M | 27.56M | 28.47M |
| Total Equity | 68.63M | 41.27M | 33.14M | 53.35M | 3.29M |
| Quarter End | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -59.56M | -15.87M | -28.91M | -35.09M | -36.71M |
| Investing | -81k | -36k | -152k | -256k | -263k |
| Financing | 66.37M | 2.19M | 1.4M | 2.51M | 1.85M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -72.72M | -71.89M | -71.33M | -59.56M | -36.71M |
| Investing | -4.6M | 331k | -274k | -81k | -263k |
| Financing | 92.92M | 56.08M | 26.92M | 66.37M | 1.85M |
| Market Cap | 0 |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 0 |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | -8.97% |
| 52 Week High | 2.24 |
| 52 Week Low | 1.35 |
| Spread (Intraday) | 0.06 (4.08%) |
| Company Name | Nabriva Therapeutics PLC |
| Address |
25-28 north wall quay dublin |
| Website | https://www.nabriva.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
